17 June 2021
Visiongain has launched a new report Companion Diagnostics (CDx) Market Report 2021-2031: Forecasts by Product & Services (Assay, Kit, Software & Service, Software & Services), by Technology (PCR, ISH, NGS, IHC, Others (Multiplex Assay and Cellular Imaging Technologies)), by Indication (Cardiovascular, Neurological Diseases, Cancer, Infectious Diseases, Others (inflammatory and inherited diseases)), by End-User (Pharmaceutical & Biopharmaceutical Companies, Reference Laboratories, CROs, Others (Physicians, Hospitals, Academic Medical Centers, Payers) AND Regional and Leading National Market Analysis PLUS Analysis of Leading CDx Companies AND COVID-19 Recovery Scenarios.
Global Companion Diagnostics Market Outlook
According to Visiongain analysis, Global Companion Diagnostics Market was valued at US$xxmillion in 2020 and is projected to reach at a market value of US$xx million by 2031. The Global market is expected to grow at a CAGR of 13.9% during the forecast period 2021-2031.
Key Questions Answered by this Report:
• What is the current size of the overall global companion diagnostics market? How much will this market be worth from 2021 to 2031?
• What are the main drivers and restraints that will shape the overall Companion Diagnostics market over the next ten years?
• What are the main segments within the overall Companion Diagnostics market?
• How much will each of these segments be worth for the period 2021 to 2031?
• How will the composition of the market change during that time, and why?
• What factors will affect that industry and market over the next ten years?
• What are the largest national markets for the world Companion Diagnostics?
• What is their current status and how will they develop over the next ten years?
• What are their revenue potentials to 2031?
• How will political and regulatory forces influence regional markets?
• How will market shares of the leading national markets change by 2031, and which geographical region will lead the market in 2031?
• Who are the leading companies and what are their activities, results, developments and prospects?
• What are the leading Companion Diagnostics? What are their revenues and latest developments?
• What are some of the most prominent Companion Diagnostics currently in development?
• What are the main trends that will affect the world Companion Diagnostics market between 2021 and 2031?
• What are the main strengths, weaknesses, opportunities and threats for the market?
• What are the social, technological, economic and political influences that will shape that industry over the next ten years?
• How will the global Companion Diagnostics market evolve over the forecasted period, 2021 to 2031?
• What will be the main commercial drivers for the market from 2021 to 2031?
• How will market shares of prominent national markets change from 2021, and which countries will lead the market in 2031, achieving highest revenues and fastest growth?
• How will that industry evolve between 2021 and 2031, especially in R&D?
Companion Diagnostics for Cancer Application is gaining traction in the global market. Find out why.
Companion diagnostics are appealing for cancer diagnosis because of increasing demand of precision medicine, availability of funding for cancer diagnostics and therapeutics, and increase in R&D activities. Companion diagnostic aids in identifying patients who are most likely to benefit from a cancer therapeutic product. Significant adoption of companion diagnostics for cancer applications has been observed. Major companies and contract manufacturers such as Thermo Fisher Scientific and Roche provide companion diagnostic products for cancer in different countries. Additionally rising demand of personalized medicine and growing use of biomarkers for cancer diagnosis are expected to boost the demand.
Discover sales predictions for the global companion diagnostics market and submarkets
Over the last few years, companion diagnostics has gained widespread attention due to the technological advancements, growing demand for precision medicine, and accelerating demand for targeted therapy. Along with revenue prediction for the overall world market, there are 4 segmentations of the Companion Diagnostics market, with forecasts for 2 products & services, 5 Technologies, 4 Indications, 3 End Users, each forecasted at a global, regional, and country level, along with COVID-19 impact recovery pattern analysis for all segments.
Who are the leading players analysed in the market?
• Abbott Laboratories, Inc.
• Abnova Corporation
• Agilent Technologies, Inc.
• Almac Group
• Biogenex Laboratories, Inc.
• bioMérieux SA
• Danaher Corporation
• Guardant Health, Inc.
• Icon Plc
• Illumina, Inc.
• Myriad Genetics, Inc.
• QIAGEN N.V.
• Roche Diagnostic
• Sysmex Corporation
• Thermo Fisher Scientific Inc.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 20 7549 9987.
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
Over the last few years, Direct-to-Patient has gained widespread attention. DTP companies offer their customers, who are patients, in this case, all kinds of services.
21 July 2021
Rising geriatric population, increasing prevalence of chronic and infectious diseases, escalating investment in drug R&D by biopharmaceutical companies, rising demand for advanced drug delivery technologies for chronic treatment are some of the major factors that drive the growth of the global drug delivery technologies market.
20 July 2021
Pharma services companies are widening their service offerings (either organically or inorganically through M&A) to become full-service providers, simplifying their customers’ operations and gaining the maximum share of their outsourcing budgets, driven by the willingness of pharma to reduce the number of outsourcers they use.
14 July 2021
Digital innovation in clinical trials and renewed focus on home production will ensure a high growth market for supply chain optimisation.